High-sensitivity C-reactive protein as a biomarker of risk in coronary artery disease;Proteína C reativa de alta sensibilidade como biomarcador de risco na doença corońaria

Revista Portuguesa de Cardiologia

Volumn 31, Issue 11, 2012, Pages 733-745

  Silva, Doroteia ^a   Pais De Lacerda, António ^a  

^a HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

Coronary artery disease; High sensitivity C reactive protein; Vascular inflammation

Indexed keywords

C REACTIVE PROTEIN;

CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DISEASE MARKER; EVIDENCE BASED MEDICINE; REVIEW; RISK ASSESSMENT;

EID: 84871496140     PISSN: 08702551     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.repc.2012.02.018     Document Type: Short Survey

References (93)

1. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 2001;104:365-72. (Pubitemid 32666962)
2. Libby P. Changing concepts of atherogenesis. J Intern Med. 2000;247:349-58. (Pubitemid 30180037)
3. Liao JK. Beyond lipid lowering: the role of statins in vascular protection. Int J Cardiol. 2002;86:5-18. (Pubitemid 35247880)
4. Inoue T, Uchida T, Yaguchi I, et al. Stent-induced expression and activation of the leukocyte integrin Mac-1 is associated with neointimal thickening and restenosis. Circulation. 2003;107:1757-63. (Pubitemid 36418356)
5. Kinlay S, Egido J. Inflammatory biomarkers in stable atherosclerosis. Am J Cardiol. 2006;98(11A).
6. Kinlay S, Selwyn AP. Effects of statins on inflammation in patients with acute and chronic coronary syndromes. Am J Cardiol. 2003;91:9-13.
7. Calabrò P, Golia E, Yeh ET. CRP and risk of atherosclerotic events. Semin Immunopathol. 2009;31:79-94.
8. Deodhar SD. C-reactive protein: the best laboratory indicator available for monitoring disease activity. Cleve Clin J Med. 1989;56:126-30. (Pubitemid 19168214)
9. Macy E, Hayes T, Tracy R. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference interval and epidemiologic applications. Clin Chem. 1997;43:52-8. (Pubitemid 27024390)
10. Ishikawa T, Hatakeyama K, Imamura T, et al. Involvement of C-reactive protein obtained by directional coronary atherectomy in plaque instability and developing restenosis in patients with stable or unstable angina pectoris. Am J Cardiol. 2003;91:287-92. (Pubitemid 36143867)
11. Inoue X Kato T, Uchida T, et al. Local release of C-reactive protein from vulnerable plaque or coronary arterial wall injured by stenting. J Am Coll Cardiol. 2005;46:239-45.
12. Cook DG, Mendall AAA, Whincup PH, et al. C-reactive protein concentration in children: relationship to adiposity and other cardiovascular risk factors. Atherosclerosis. 2000;149:139-50. (Pubitemid 30125982)
13. Mendall MA, Patel P, Ballam L, et al. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. Br Med J. 1996;312:1061-5. (Pubitemid 26125131)
14. Wu SL, Li JF, Li Y, et al. The distribution and influential factors of serum high sensitivity C-reactive protein in general population. Zhonghua Nei Ke Za Zhi. 2010;49:1010-4.
15. Kuller LH, Tracy RP, Shaten J, et al. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol. 1996;144:537-47. (Pubitemid 26304398)
16. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-9. (Pubitemid 27152782)
17. Koenig W, Sund M, Fröhlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men. Circulation. 1999;99:237-42.
18. Geluk CA, Post WJ, Hillege HL, et al. C-reactive protein and angiographic characteristics of stable and unstable coronary artery disease: data from the prospective PREVEND cohort. Atherosclerosis. 2008;196:372-82.
19. Ridker P, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-43. (Pubitemid 30165206)
20. Ridker P, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-65. (Pubitemid 35315836)
21. Ridker PM. High sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001;103:1813-8. (Pubitemid 32291421)
22. Ridker PM, Buring JE, Rifai N, et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk score. JAMA. 2007;297:611-9.
23. Ridker PM, Paynter NP, Rifai N, et al. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation. 2008;118:2243-51.
24. Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation. 2003;107:391-7.
25. Oh EG, Kim SH, Bang SY, et al. High-sensitivity C-reactive protein is independently associated with arterial stiffness in women with metabolic syndrome. J Cardiovasc Nurs. 2012;27:61-7.
26. Pradhan AD, Ridker PM. Do atherosclerosis and type 2 diabetes share a common inflammatory basis? Eur Heart J. 2002;23:831-4. (Pubitemid 34717414)
27. Guran O, Akalin F, Ayabakan C, et al. High-sensitivity C-reactive protein in children at risk for coronary artery disease. Acta Paediatr. 2007;96:1214-9. (Pubitemid 47106518)
28. Sattar N, Lowe GD. High sensitivity C-reactive protein and cardiovascular disease: an association built on unstable foundations? Ann Clin Biochem. 2006;43:252-6. (Pubitemid 44049687)
29. Danesh J, Wheeler JG, Hirschfield GM. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-97. (Pubitemid 38419992)
30. Lloyd-Jones DM, Liu K, Tian L. Assessment of C-reactive protein in risk prediction for cardiovascular disease. Ann Intern Med. 2006;145:35-42. (Pubitemid 46780605)
31. Wang TJ, Gona P, Larson MG. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355:2631-9. (Pubitemid 44969122)
32. Blankenberg S, Zeller T, Saarela O. Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation. 2010 8;121:2388-97.
33. Libby P, Crea F. Clinical implications of inflammation for cardiovascular primary prevention. Eur Heart J. 2010;31:777-83.
34. Masood A, Jafar SS, Akram Z. Serum high sensitivity C-reactive protein levels and the severity of coronary atherosclerosis assessed by angiographic gensini score. J Pak Med Assoc. 2011;61:325-7.
35. Bamberg F, Truong QA, Koenig W, et al. Differential associations between blood biomarkers of inflammation, oxidation, and lipid metabolism with varying forms of coronary atherosclerotic plaque as quantified by coronary CT angiography. Int J Cardiovasc Imaging. 2012;28:183-92.
36. He P, Xie XH, Ding YP, et al. Correlation between high sensitive C-reactive protein, lipoprotein(a), blood uric acid and severity of coronary artery disease. Zhonghua Yi Xue Za Zhi. 2010;90:1989-91.
37. Peer A, Falkensammer G, Alber H, et al. Limited utilities of N-terminal pro B-type natriuretic peptide and other newer risk markers compared with traditional risk factors for prediction of significant angiographic lesions in stable coronary artery disease. Heart. 2009;95:297-303.
38. Hosseinsabet A, Mohebbi A, Almasi A. Association between C-reactive protein and coronary calcium score in coronary artery disease. Cardiovasc J Afr. 2009;20:107-11.
39. Lin T, Liu JC, Chang LY, et al. Association of C-reactive protein and homocysteine with subclinical coronary plaque subtype and stenosis using low-dose MDCT coronary angiography. Atherosclerosis. 2010;212:501-6.
40. Kadi H, Ceyhan K, Karayakali M, et al. The relationship between coronary collateral circulation and blood high-sensitivity C-reactive protein levels. Turk Kardiyol Dern Ars. 2011;39:23-8.
41. Kerner A, Gruberg L, Goldberg A, et al. Relation of C-reactive protein to coronary collaterals in patients with stable angina pectoris and coronary artery disease. Am J Cardiol. 2007;99:509-12. (Pubitemid 46215557)
42. Sinning JM, Bickel C, Messow CM, et al. Impact of C-reactive protein and fibrinogen on cardiovascular prognosis in patients with stable angina pectoris: the Athero Gene study. Eur Heart J. 2006;27:2962-8. (Pubitemid 44950439)
43. Sabatine MS, Morrow DA, Jablonski KA, et al. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation. 2007;115:1528.
44. Arroyo-Espliguero R, Avanzas P, Quiles J, et al. C-reactive protein predicts functional status and correlates with left ventricular ejection fraction in patients with chronic stable angina. Atherosclerosis. 2009;205:319-24.
45. Arroyo-Espliguero R, Avanzas P, Quiles J, et al. Predictive value of coronary artery stenoses and C-reactive protein levels in patients with stable coronary artery disease. Atherosclerosis. 2009;204:239-43.
46. Worthley SG, Farouque HM, Cameron JD, et al. Arterial remodeling correlates positively with serological evidence of inflammation in patients with chronic stable angina pectoris. J Invasive Cardiol. 2006;18:28-31.
47. Kubo T, Matsuo Y, Hayashi Y, et al. High-sensitivity C-reactive protein and plaque composition in patients with stable angina pectoris: a virtual histology intravascular ultrasound study. Coron Artery Dis. 2009;20:531-5.
48. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1998;98:839-44. (Pubitemid 28397432)
49. Zouridakis E, Avanzas P, Arroyo-Espliguero R, et al. Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris. Circulation. 2004;110:1747-53. (Pubitemid 39299216)
50. Beattie MS, Shlipak MG, Liu H, et al. C-reactive protein and ischemia in users and nonusers of beta-blockers and statins: data from the Heart and Soul Study. Circulation. 2003;107:245.
51. Sano T, Tanaka A, Namba M, et al. C-reactive protein and lesion morphology in patients with acute myocardial infarction. Circulation. 2003;108:282-5. (Pubitemid 36899017)
52. Stefanadis C, Diamantopoutos L, Dernellis J, et al. Heat production of atherosclerotic plaques and inflammation assessed by the acute phase proteins in acute coronary syndromes. J Mol Cell Cardiol. 2000;32:43-52. (Pubitemid 30064303)
53. Smit JJ, Ottervanger JP, Slingerland RJ, et al., On-TIME Study Group. Comparison of usefulness of C-reactive protein versus white blood cell count to predict outcome after primary percutaneous coronary intervention for ST elevation myocardial infarction. Am J Cardiol. 2008;101:446-51. (Pubitemid 351199429)
54. Brunetti ND, Troccoli R, Correale M, et al. C-reactive protein in patients with acute coronary syndrome: correlation with diagnosis, myocardial damage, ejection fraction and angiographic findings. Int J Cardiol. 2006;109:248-56.
55. Morrow DA, Rifai N, Antman EM, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI11A substudy. J Am Coll Cardiol. 1998;31:1460-5. (Pubitemid 28273285)
56. Lindahl B, Toss H, Siegbahn A, et al. Markersof myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. N Engl J Med. 2000;343:1139-47.
57. James SK, Armstong P, Barnathan E, et al. Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy. J Am CollCardiol. 2003;41:916-24. (Pubitemid 36315530)
58. Foussas SG, Zairis MN, Lyras AG, et al. Early prognostic usefulness of C-reactive protein added to the Thrombolysis In Myocardial Infarction risk score in acute coronary syndromes. Am J Cardiol. 2005;96:533-7. (Pubitemid 41132770)
59. Mueller C, Buettner HJ, Hodgson JM, et al. Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients. Circulation. 2002;105:1412-5. (Pubitemid 34263269)
60. Zairis M, Manousakis S, Stefanidis A, et al. C-reactive protein levels on admission are associated with response to thrombolysis and prognosis after ST-segment elevation acute myocardial infarction. Am Heart J. 2002;144:782-9. (Pubitemid 35335168)
61. Nakachi T, Kosuge M, Hibi K, et al. C-reactive protein elevation and rapid angiographic progression of nonculprit lesion in patients with non-ST-segment elevation acute coronary syndrome. Circ J. 2008;72:1953-9.
62. Zebrack JS, Anderson JL, Maycock CA, et al., The Intermountain Heart Collaborative (IHC) Study Group. Usefulness of high-sensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction. Am J Cardiol. 2002;89:145-9. (Pubitemid 34132900)
63. Bogaty P, Boyer L, Simard S, et al. Clinical utility of C-reactive protein measured at admission, hospital discharge, and 1 month later to predict outcome in patients with acute coronary disease. The RISCA (recurrence and inflammation in the acute coronary syndromes) study. J Am Coll Cardiol. 2008;51:2339-46. (Pubitemid 351784544)
64. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344:1959-65. (Pubitemid 32568149)
65. Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. J Am Med Assoc. 2001;286:64-70. (Pubitemid 32606333)
66. Walsh JM, Pignone M. Drug treatment of hyperlipidemia in women. JAMA. 2004;291:2243-52. (Pubitemid 38608174)
67. Petretta M, Costanzo P, Perrone-Filardi P, et al. Impact of gender in primary prevention of coronary heart disease with statin therapy: a meta-analysis. Int J Cardiol. 2010;138:25-31.
68. Thavendiranathan P, Bagai A, Brookhart MA, et al. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med. 2006;166:2307-13. (Pubitemid 44833354)
69. Mizuno K, Nakaya N, Ohashi Y, et al. Usefulness of pravastatin in primary prevention of cardiovascular events in women: analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA study). Circulation. 2008;117:494-502.
70. Ridker PM, Danielson E, Fonseca FA, et al., JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-207.
71. Mora S, Glynn RJ, Hsia J. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation. 2010;121:1069-77.
72. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:2376.
73. Choudhry NK, Patrick AR, Glynn RJ, et al. The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels. J Am Coll Cardiol. 2011;57:784-91.
74. MacDonald GP. Cost-effectiveness of rosuvastatin for primary prevention of cardiovascular events according to Framingham Risk Score in patients with elevated C-reactive protein. J Am Osteopath Assoc. 2010;110:427-36.
75. Lee KK, Cipriano LE, Owens DK, et al. Cost-effectiveness of using high-sensitivity C-reactive protein to identify intermediate- and low-cardiovascular-risk individuals for statin therapy. Circulation. 2010;122:1478-87.
76. Rashid S. Key questions resulting from the JUPITER trial assessing cardiovascular disease intervention with rosuvastatin. World J Cardiol. 2009;1:41-5.
77. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20-8. (Pubitemid 40075677)
78. Morrow DA, de Lemos JA, Sabatine MS, et al. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation. 2006;114:281-8. (Pubitemid 44297094)
79. Feldman M, Jialal I, Devaraj S, et al. Effects of low dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay. J Am Coll Cardiol. 2001;37:2036-41. (Pubitemid 32547994)
80. Bogaty P, Brophy JM, Boyer L, et al. Fluctuating inflammatory markers in patients with stable ischemic heart disease. Arch Intern Med. 2005;165:221-6.
81. Blum A, Costello R, Samsel L, et al. Variability of C-reactive protein levels among patients with stable coronary artery disease and on statin therapy. Isr Med Assoc J. 2009;11:602-5.
82. Sakkinen PA, Macy EM, Callas PW, et al. Analytical and biologic variability in measures of hemostasis, fibrinolysis, and inflammation: assessment and implications for epidemiology. Am J Epidemiol. 1999;149:261-7. (Pubitemid 29053167)
83. Kushner I, Sehgal AR. Is high-sensitivity C-reactive protein an effective screening test for cardiovascular risk? Arch Intern Med. 2002;162:867-9. (Pubitemid 34299117)
84. de Maat MP, de Bart AC, Hennis BC, et al. Interindividual and intraindividual variability in plasma fibrinogen, TPA antigen, PAI activity, and CRP in healthy, young volunteers and patients with angina pectoris. Arterioscler Thromb Vasc Biol. 1996;16:1156-62. (Pubitemid 26299288)
85. Sennels HP, Jacobsen S, Jensen T, et al. Biological variation and reference intervals for circulating osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor kappa B ligand and high-sensitivity C-reactive protein. Scand J Clin Lab Invest. 2007;67:821-35. (Pubitemid 350158770)
86. Nasermoaddeli A, Sekine M, Kagamimori S. Intra-individual variability of high-sensitivity C-reactive protein: age-related variations over time in Japanese subjects. Circ J. 2006;70:559-63.
87. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511. (Pubitemid 36158056)
88. NACB LMPG Committee MembersMyers GL, Christenson RH, Cushman M, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease. Clin Chem. 2009;55:378-88.
89. Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol. 2009;25:567-79.
90. Graham I, Atar D, Borch-Johnsen K, et al. ESC Committee for Practice Guidelines. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Atherosclerosis. 2007;194:1-45. (Pubitemid 47470068)
91. FDA approves new indication for Crestor [press release]. Washington, DC: US Food and Drug Administration; February 9, 2010. [consultado 17 Jul 2010]. Disponível em: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm200128.htm
92. Messerli FH, Mancia G, Conti CR, et al. Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J. 2006;27:2902-3. (Pubitemid 44871478)
93. Hemingway H, Philipson P, Chen R, et al. Evaluating the quality of research into a single prognostic biomarker: a systematic review and meta-analysis of 83 studies of C-reactive protein in stable coronary artery disease. PLoS Med. 2010;7:e1000286.